The luminol-amplified chemiluminescence of neutrophils and monocytes in patients with gastric cancer after intraoperative radiotherapy using radiosensitizer sanazole.
The effect of electron-beam intraoperative radiotherapy (IORT) with radiosensitizer sanazole (drug AK-2123) on the functional activity of neutrophils and monocytes in patients with gastric cancer was studied with the use of luminol-amplified chemiluminescence. Sanazole was administered intravenously in a dose of 1.2 g/m2, 30 min before IORT. After resection of the tumor a single dose of 10 Gy was given to the field of regional lymph collectors and the bed of the removed tumor applying a small-size betatron MIB-6E. Cells were separated and chemiluminescence was estimated on the 1-st day before and on the 3-d day and 2-d week after IORT with sanazole. Insignificant effect on the zymosan- or phorbol-12 -myristate-13-acetate (PMA)-stimulated chemiluminescence was observed in this group, although there was found a considerable increase of chemiluminescence of neutrophils in response to zymosan and PMA in 5 from 8 patients, and chemiluminescence of monocytes--in 3 from 8 patients. Correlation between individual indices of zymosan- and PMA-stimulated chemiluminescence of neutrophils before IORT with sanazole was not high, r = 0.71, but it increased significantly to r = 0.91 on the 3-d day and to r = 0.96 on 2-d week after treatment. Correlation between individual indices of stimulated chemiluminescence of monocytes before IORT with sanazole was r = 0.90, and increased to r = 0.99 on the 3-d day and to r = 0.96 on the 2-d week after treatment. So, it is indicative of a correcting effect of the combined treatment including IORT with sanazole administration on the functional activity of neutrophils and monocytes, and the absence of functional disturbances of these cells.
Schepetkin
I
I
Immunology Department, Tomsk Research Center, Russian Academy of Medical Sciences, Russia.
Cherdyntseva
N
N
Afanasjev
S
S
Antipov
S
S
Zyryanov
B
B
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D000368:Aged; D005260:Female; D006801:Humans; D007432:Intraoperative Period; D008163:Luminescent Measurements; D008165:Luminol; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D018375:Neutrophil Activation / Q000187:drug effects / Q000528:radiation effects; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014230:Triazoles / Q000627:therapeutic use*
D011838:Radiation-Sensitizing Agents; D014230:Triazoles; C072690:AK 2123; D008165:Luminol; D013755:Tetradecanoylphorbol Acetate